An increasing proportion of women with heart disease now go through pregnancy and childbirth. More knowledge about the risk of complications and adverse outcomes for the mother and the baby is needed to guide clinical care in this diverse patient group. The purpose of this study is to, in a cohort of pregnant women with heart disease; * determine fetal growth, and risk of fetal growth restriction and preterm birth * determine whether maternal blood biomarkers are associated with development of preeclampsia, the time of delivery and maternal and perinatal adverse outcomes * determine the risk of hypertensive pregnancy complications The expected outcome of the project is to increase the knowledge of optimal diagnosis and treatment of women with heart disease that go through pregnancy to be able to improve clinical care and the outcomes for mother and baby.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Fetal growth
Timeframe: From gestational week 12 until time of birth of baby
Occurrence of hypertension/preeclampsia in pregnancy or postpartum
Timeframe: From time of study inclusion until time of discharge from maternity unit after birth of baby
Fetoplacental circulation
Timeframe: From gestational week 12 until time of birth of baby